Search research articles
Contact Us
Filters
Showing results (31-40 of 54) with videos related to
Page
of 6
Sort By:
Breast Cancer Research and Treatment
|
May 12, 2016
Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases
William Jacot, Elvire Pons, Jean-Sébastien Frenel, et al.
Respiratory Research
|
April 5, 2024
Use of non-small cell lung cancer multicellular tumor spheroids to study the impact of chemotherapy
Pauline Hulo, Sophie Deshayes, Judith Fresquet, et al.
Clinical Lung Cancer
|
May 29, 2026
Impact of Immune Checkpoint Inhibitor-Combined Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer With Brain Metastases
Amira Aliouat, Agathe Chareire, Teo Bodergat, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 2, 2019
Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
Khalil Saleh, Amaury Daste, Nicolas Martin, et al.
JCO Precision Oncology
|
February 1, 2022
Comparative Analysis of Durable Responses on Immune Checkpoint Inhibitors Versus Other Systemic Therapies: A Pooled Analysis of Phase III Trials
Elvire Pons-Tostivint, Aurélien Latouche, Pauline Vaflard, et al.
Drugs in R&D
|
September 25, 2021
Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy
Pauline Vaflard, Xavier Paoletti, Vincent Servois, et al.
Oncoimmunology
|
July 15, 2024
Interplay between oncolytic measles virus, macrophages and cancer cells induces a proinflammatory tumor microenvironment
Camille Chatelain, Laurine Berland, Marion Grard, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 26, 2025
Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 LEAP-006 Study
Roy S Herbst, Byoung Chul Cho, Caicun Zhou, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 23, 2026
Corrigendum to 'Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC' [Journal of Thoracic Oncology Volume 20 Issue 12 (2025) 1814-1828]
Pasi A Jänne, Yasushi Goto, Toshio Kubo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 1, 2025
Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC
Pasi A Jänne, Yasushi Goto, Toshio Kubo, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 54) with videos related to
Sort By:
Page
of 6
Breast Cancer Research and Treatment
|
May 12, 2016
Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases
William Jacot, Elvire Pons, Jean-Sébastien Frenel, et al.
Respiratory Research
|
April 5, 2024
Use of non-small cell lung cancer multicellular tumor spheroids to study the impact of chemotherapy
Pauline Hulo, Sophie Deshayes, Judith Fresquet, et al.
Clinical Lung Cancer
|
May 29, 2026
Impact of Immune Checkpoint Inhibitor-Combined Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer With Brain Metastases
Amira Aliouat, Agathe Chareire, Teo Bodergat, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 2, 2019
Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
Khalil Saleh, Amaury Daste, Nicolas Martin, et al.
JCO Precision Oncology
|
February 1, 2022
Comparative Analysis of Durable Responses on Immune Checkpoint Inhibitors Versus Other Systemic Therapies: A Pooled Analysis of Phase III Trials
Elvire Pons-Tostivint, Aurélien Latouche, Pauline Vaflard, et al.
Drugs in R&D
|
September 25, 2021
Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy
Pauline Vaflard, Xavier Paoletti, Vincent Servois, et al.
Oncoimmunology
|
July 15, 2024
Interplay between oncolytic measles virus, macrophages and cancer cells induces a proinflammatory tumor microenvironment
Camille Chatelain, Laurine Berland, Marion Grard, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 26, 2025
Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 LEAP-006 Study
Roy S Herbst, Byoung Chul Cho, Caicun Zhou, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 23, 2026
Corrigendum to 'Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC' [Journal of Thoracic Oncology Volume 20 Issue 12 (2025) 1814-1828]
Pasi A Jänne, Yasushi Goto, Toshio Kubo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 1, 2025
Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC
Pasi A Jänne, Yasushi Goto, Toshio Kubo, et al.
Page
of 6